Previous 10 | Next 10 |
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets (*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad is approved for use by the U.S. Food & Drug Administration (as part of the Thermage FLX device r...
2024-01-18 13:26:46 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript Bausch Health Companies Inc. 2023 Q3 - Results - Earnings Call Presentation B...
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets LAVAL, QC / ACCESSWIRE / January 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of The...
2024-01-17 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 13:53:28 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript Bausch Health Companies Inc. 2023 Q3 - Results - Earnings Call Presentation B...
2024-01-08 08:31:17 ET More on Bausch Health, Bausch + Lomb, etc. Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade) Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript Bausch re...
2023-12-21 12:59:06 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch Health Companies Inc. (BHC) Q3 2023 Earnings Call Transcript Bausch Health Companies Inc. 2023 Q3 - Results - Earnings Call Presentation B...
Trial Meets Both Primary and Key Secondary Endpoints LAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigat...
2023-12-19 22:37:01 ET Summary John Paulson's 13F portfolio value increased by 9% to $1.12 billion this quarter. The top five positions in the portfolio were Horizon Therapeutics, Bausch Health, Brightsphere Investment Group, NovaGold, and Perpetua Resources. Paulson's stake i...
LAVAL, QC / ACCESSWIRE / December 18, 2023 / Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), ("Bausch Health" or the "Company") today announced that DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), the company's novel topical prescrip...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC Stock Symbol:
NYSE Market:
2024-05-06 10:47:03 ET Bausch Health Companies Inc (BHC) BHC is trading DOWN for the last 4 days, and it at trading at $7.69 with volume of 1,380,917 and a one day change of $-0.14 (-1.73%). Bausch Health Companies Inc has a 52-week low of 5.57 and a 52-week high of $11.46. The busi...
2024-05-02 18:43:30 ET Eyecare specialist Bausch Health Companies (NYSE: BHC) wasn't a clear winner on the stock exchange Thursday, to put it charitably. After unveiling its latest earnings report it was met with a sell-off, as investors drove its share price down by over 7%. That w...
Bausch Health Companies Inc. (NYSE:BHC) shares are trading lower on Thursday after reporting first-quarter results. The company reported ...